About: Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection
Creator	Bangi, Shifa Barve, Rajas Qamar, Amna
Source	Medline; PMC
abstract	Despite the burden of disease of CVD and DM, there is a lack of experimentally validated literature exploring their association with exacerbation of COVID-19. Target receptors of medications commonly used to treat CVD and DM may be involved in the viral entry mechanism of SARS-CoV-2. We propose the potential protective effects of these medications in COVID-19 infections, highlighting the need for further research. Firstly, AMPK mediated phosphorylation of ACE-2 by metformin as well as the drug’s alkaline properties may interrupt the natural disease progression. Secondly, DPP4 receptor involvement in the putative viral entry of SARS-CoV-2 may be prevented by DPP4i. Finally, recent studies have shown that statins’ ability to inhibit the cytokine storm may outweigh concerns of statin mediated ACE-2 upregulation in COVID-19. The complex interplay of factors affecting CVD and DM in COVID-19 patients makes the direct effects of medications difficult to examine. Therefore, further research is needed, in the context of SARS-CoV-2 and the molecular pathways it exploits, to potentially repurpose such pre-existing drugs for their use in COVID-19.
has issue date	2020-08-17(xsd:dateTime)
bibo:doi	10.1007/s42399-020-00452-4
bibo:pmid	32838195
has license	cc-by
sha1sum (hex)	645da2b1cc886d1f966a321313e0d6c683564330
schema:url	https://doi.org/10.1007/s42399-020-00452-4
resource representing a document's title	Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection
has PubMed Central identifier	PMC7431108
has PubMed identifier	32838195
schema:publication	SN Compr Clin Med
resource representing a document's body	covid:645da2b1cc886d1f966a321313e0d6c683564330#body_text
is schema:about of	named entity 'progression' named entity 'patients' named entity 'PHOSPHORYLATION' named entity 'MECHANISM' named entity 'NEED FOR' named entity 'CONTEXT' named entity 'THESE' named entity 'TO EXAMINE' named entity 'LITERATURE' named entity 'MAY BE' named entity 'DRUGS' named entity 'viral entry' named entity 'commonly' named entity 'CVD' named entity 'mechanism' named entity 'repurpose' named entity 'statins' named entity 'CVD' named entity 'AMPK' named entity 'COVID-19' named entity 'CVD' named entity 'phosphorylation' named entity 'COVID' named entity 'COVID-19' named entity 'Infection' named entity 'metformin' named entity 'hypertension' named entity 'SARS-CoV-2' named entity 'AMPK' named entity 'statins' named entity 'statins' named entity 'statins' named entity 'virus' named entity 'DPP4' named entity 'conformational change' named entity 'rodent models' named entity 'cardiac complications' named entity 'vaccine' named entity 'randomized controlled trials' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'Creative Commons licence' named entity 'Experimental validation' named entity 'gliptins' named entity 'all-cause mortality' named entity 'ACE inhibitors' named entity 'host cells' named entity 'statins' named entity 'respiratory tract' named entity 'cardiovascular disease' named entity 'COVID' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'renin-angiotensin' named entity 'metformin' named entity 'coronary heart disease' named entity 'preventing disease' named entity 'infection' named entity 'metformin' named entity 'immune dysfunction' named entity 'mechanism of action' named entity 'All-cause mortality' named entity 'ACE2' named entity 'molecular pathways' named entity 'gliptins' named entity 'ACE2' named entity 'ACE2' named entity 'diabetics' named entity 'first-line treatment' named entity 'Gliptins' named entity 'chronic kidney disease' named entity 'SARS-CoV-2' named entity 'DPP4' named entity 'observational studies' named entity 'ACE2' named entity 'control patients' named entity 'ACE2' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software